Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 13, 2026
TickeronGET DAILY SIGNALS
Owlet (OWLT) Drops -35% in 30 Days After Q3 Results and Safety Update

Owlet (OWLT) Drops -35% in 30 Days After Q3 Results and Safety Update

Key Takeaways

  • OWLT fell roughly 35% over the last 30 days, sliding from about $4.41 to near $2.86.
  • The decline accelerated sharply after Owlet reported third-quarter 2026 results and withdrew its full-year 2026 financial outlook.
  • A newly initiated camera cable guard safety update, tied to a reported safety incident involving exposed camera cables, added significant pressure.
  • Management cited anticipated remediation expenses, a fourth-quarter retail sales interruption, retailer returns, and near-term demand uncertainty.
  • Underlying positives were overshadowed: Q3 revenue of $30.4 million, record subscription revenue of $3.6 million, and more than 142,000 Owlet360 subscribers.
  • Over the last quarter, OWLT has declined more than 50%, extending a multi-month downtrend.
  • For more detail on valuation and expectations, explore the ticker's Price Targets, Earnings, and Forecast pages.

Owlet (OWLT) Company Background and Market Position

Owlet, Inc. (OWLT), headquartered in Lehi, Utah, operates as a pediatric health platform focused on infant and child monitoring. The company is best known for its Dream Sock wearable monitor, which tracks a baby's pulse rate and oxygen levels, and its Dream Duo and Dream Sight camera products. Owlet positions itself as the only company in the world offering U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade monitoring in the home. Since 2012, more than 2.5 million parents have used its products, according to the company.

Beyond hardware, Owlet has been building a recurring-revenue software business through its Owlet360 subscription service and its Owlet OnCall telehealth initiative. I follow OWLT closely because of its regulatory moat, its transition toward subscription revenue, and its expansion into a broader connected pediatric health ecosystem that includes the recently launched Smart Thermometer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Owlet (OWLT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, OWLT declined approximately 35%. The stock traded near $4.41 in mid-October and fell to roughly $2.86 by mid-November. Most of that decline occurred in a single session, when shares dropped about 38% following the company's third-quarter earnings release and outlook withdrawal.

The quarterly picture is even weaker. About three months earlier, OWLT traded near $6.27, meaning the stock has lost more than half its value — roughly 54% — over the last quarter. After peaking around $6.66 in mid-August, the shares trended steadily lower through September and October before the November earnings-driven selloff pushed them to their lowest levels of the period.

What Drove OWLT Stock Price in the Last 30 Days

The dominant catalyst was Owlet's third-quarter 2026 report on November 13. Revenue came in at $30.4 million, down 4.9% from $32.0 million a year earlier, while net income fell to $1.4 million from $4.2 million. Although reported earnings per share of $0.11 beat consensus estimates, the company withdrew its full-year 2026 outlook, citing anticipated remediation expenses, a fourth-quarter retail sales interruption, retailer returns, and near-term demand uncertainty.

The withdrawal was tied to a safety update: after receiving a safety incident report involving exposed camera cables, Owlet initiated a camera cable guard update and began shipping replacement enclosed cable guard systems free of charge. The near-term costs and expected retail disruption outweighed otherwise encouraging metrics, including record subscription revenue of $3.6 million, a gross margin that expanded to 53.8%, and paying subscribers that grew to more than 142,000. The launch of the FDA-registered Smart Thermometer in early November provided a positive product milestone but was not enough to offset the guidance removal.

What Drove OWLT Stock Performance Over the Last Quarter

The multi-month decline reflects a broader shift in sentiment around near-term growth and profitability. In August, Owlet reported better-than-expected second-quarter results, and shares briefly rallied. However, an August 10 FDA enforcement deadline for vital-signs baby monitors triggered aggressive competitor discounting, which management said pressured third-quarter sales. Amazon subsequently removed non-compliant third-party products, leaving Dream Sock as the only baby monitor on the platform tracking instant vital signs, but the near-term competitive disruption weighed on results.

Investor focus gradually shifted from the company's strengthening subscription economics — Owlet360 subscribers grew 83% year over year — toward concerns about hardware revenue trajectory, retail inventory dynamics, and execution risk. The November withdrawal of full-year guidance, combined with the safety update, crystallized those concerns and accelerated the quarterly downtrend. From what I see, this is important because it highlights how quickly sentiment can shift when guidance is pulled.

OWLT Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors will monitor the cost and duration of the camera cable guard safety update and any impact on fourth-quarter sales and retailer relationships. Reinstatement or revision of full-year guidance, along with management's commentary on demand recovery, will be closely watched. The trajectory of Owlet360 subscription growth, the rollout of the Smart Thermometer and Owlet OnCall telehealth features, and the pace of Dream Sock sell-through now that non-compliant competitors have been removed from Amazon are additional key factors. Analyst price targets, macroeconomic conditions affecting consumer spending, and any regulatory developments in pediatric monitoring remain important considerations. I’m watching this closely as these elements could shape the stock’s path in coming quarters.

Using Tickeron’s AI Tools for Deeper Analysis

In my view, one resource that has proven helpful for evaluating stocks like this is Tickeron’s AI Trading Bots. These automated strategies cover thousands of tickers and allow users to review performance across different timeframes and risk levels. I often reference the Trending AI Robots section to see which approaches align with current market conditions before forming a broader view on a name such as OWLT.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OWLT

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for OWLT turns positive, indicating new upward trend

OWLT saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 71 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OWLT's RSI Indicator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for OWLT just turned positive on November 02, 2026. Looking at past instances where OWLT's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.

Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where OWLT advanced for three days, in 209 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OWLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

OWLT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for OWLT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.847) is normal, around the industry mean (4.142). P/E Ratio (-13.900) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.967) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. OWLT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OWLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 0%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -6%. POAS experienced the highest price growth at 307%, while CVRX experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was 75% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
2940 West Maple Loop Drive
Phone
+1 844 334-5330
Employees
114
Web
https://www.owletcare.com
Interact to see
Advertisement
BZ dropped sharply, sliding from a $16.72 prior close to $13.48 (-19.38%), with the decline beginning in premarket and deepening into the early regular session. No verified company-specific news or fundamental catalyst was issued; the fall tracked a broad China ADR selloff (the Nasdaq Golden Dragon index slid more than 2%), but that alone is too small to explain a ~20% drop — the stock's Hong Kong listing fell only -2.6%.
NBIS fell from $154.69 to $129.12, down -16.53%, with the decline starting in premarket trading and continuing through the regular session. The drop followed Q3 results: revenue of $980.8M (+571% YoY) beat estimates, but management cut 2026 revenue guidance to the low end of its range on third-party capacity delays and raised 2026 capex to roughly $27B, reviving financing and execution fears.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
The central target of $21 is the arithmetic mean of three recently attributable analyst price targets on RUM — $25 (Lake Street), $15 (Texas Capital), and $22 (Maxim Group) — which average roughly $20.67. With shares trading near $5.90 after a post-earnings surge, reaching $21 would require a gain of roughly 256%, a very large move.
The $1 target in this article is not an analyst price target; it is the $1.00 Nasdaq minimum bid price requirement, the level Cenntro itself has publicly targeted through a 1-for-60 reverse stock split. Cenntro trades near $0.12 per share, meaning reaching $1 would require an increase of roughly 730%—an exceptionally large move.